Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 4 - You Need To See This

BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances

BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations for hereditary angioedema drug ORLADEYO, progress for late-stage HAE candidate navenibart

MarketBeat

Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline. Speaking at a Jefferies fireside chat

MarketBeat

Axon Enterprise Touts AI, Global Markets and Counter-Drone Demand as Growth Engines

Axon Enterprise (NASDAQ:AXON) President Josh Isner said the company continues to see durable growth opportunities across public safety, international markets, enterprise customers and new artificial intelligence products, speaking during a William Blair & Company fireside chat hosted by research

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead

Avalyn Pharma (NASDAQ:AVLN) executives outlined the company’s inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosi

MarketBeat

AeroVironment Sees Drone Demand Taking Off as Switchblade, Counter-Drone Capacity Expands

AeroVironment (NASDAQ:AVAV) executives told investors at William Blair’s 46th Annual Growth Stock Conference that the company sees expanding opportunities across drones, loitering munitions and counter-drone systems, while also emphasizing ongoing capacity investments tied to programs such as Switch

MarketBeat

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w

MarketBeat

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

AI Server Earnings: Wall Street Sees One Clear Standout

AI server stocks put up eye-popping gains in May and early June, with Supermicro, Dell, and HPE seeing huge pops after their latest earnings.

MarketBeat

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m

MarketBeat

Quanex Building Products Q2 Earnings Call Highlights

Quanex Building Products (NYSE:NX) reported a modest increase in fiscal second-quarter revenue but sharply lower earnings, as inflation in raw materials, freight and logistics weighed on margins and led the company to withhold reaffirmation of its prior full-year outlook. On the company’s earnings

MarketBeat

A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below

Lululemon isn't out of danger as its FQ1 release reveal new risks for investors. The stock price is moving lower and may enter freefal this summer.

MarketBeat

StealthGas Q1 Earnings Call Highlights

StealthGas (NASDAQ:GASS) reported higher first-quarter revenue and continued to emphasize its debt-free balance sheet, growing cash position and charter coverage during its first-quarter 2026 earnings call. Chairman Michael Jolliffe said revenue rose to $42.8 million in the quarter, up 2% from $42

MarketBeat

Saputo Q4 Earnings Call Highlights

Saputo (TSE:SAP) executives said the dairy processor ended fiscal 2026 with stronger margins, improved cash generation and a more focused portfolio, even as lower U.S. dairy commodity pricing weighed on reported revenue in the fourth quarter. On the company’s fourth-quarter earnings call, President

MarketBeat

G-III Apparel Group Q1 Earnings Call Highlights

G-III Apparel Group (NASDAQ:GIII) reported first-quarter fiscal 2027 results that exceeded its own expectations, as stronger gross margins and growth in its go-forward brand portfolio helped offset the planned loss of revenue tied to PVH brands. Chairman and Chief Executive Officer Morris Goldfarb

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

ABM Industries Q2 Earnings Call Highlights

ABM Industries (NYSE:ABM) reported stronger second-quarter fiscal 2026 revenue growth and record first-half new sales bookings, while management maintained its full-year adjusted earnings outlook and said it expects a stronger margin performance in the second half of the year. President and Chief E

MarketBeat

Five Below Down 12% Post Earnings—Is the Selloff Overdone?

Five Below fell more than 13% after Q1 2026 earnings beat estimates, as cautious second-half guidance and tariff uncertainty overshadowed strong revenue and EPS results.

MarketBeat

Arrow Financial Highlights Profit Gains, Adirondack Bank Deal at Annual Meeting

Arrow Financial (NASDAQ:AROW) used its virtual annual meeting to highlight what executives described as a transformational 2025, including the first full year operating under the unified Arrow Bank brand, stronger profitability metrics and progress toward its planned acquisition of Adirondack Bank.

MarketBeat

Tuniu Q1 Earnings Call Highlights

Tuniu (NASDAQ:TOUR) reported higher first-quarter revenue and its fifth consecutive quarter of non-GAAP profitability, as management said China’s travel market continued to benefit from solid demand during the period, including support from the longest Chinese New Year holiday on record. Founder, C

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

The Market Has Ollie’s Bargain Outlet Completely Wrong

Ollie's Bargain Outlet is executing strategy, growing, and widening margin but will it be enough to get the stock price action advancing?

MarketBeat

NVIDIA Sends a Message With RTX Spark—This Is What It Says

NVIDIA is in control of AI, driving its evolution at all levels of the stack as it enters the PC market. RTX Spark is another game changer for tech.

MarketBeat

argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference

argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.

MarketBeat

Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies

Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York. Payne described Arcturus as a “next generation messen

MarketBeat

Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial

MarketBeat

Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End

Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global Healthcare Conference in New York. Speaking with Jefferies analyst Marco Baruzzi, Wessman said Alvotech ha

MarketBeat

Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial

Altimmune (NASDAQ:ALT) executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, while also awaiting data from related alcohol-associated liver disease programs.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.